Please assess the completion status of the following clinical trial:

Trial Title: Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must demonstrate their willingness to participate in the study (reliable and compliant for repeated treatments) and comply with its procedures by signing a written informed consent.~2. Subjects must be 18 years of age or older.~3. Subjects must have received a platinum regimen, with or without paclitaxel or cyclophosphamide, and have maintained a disease-free status for at least 6 months following the completion of first line therapy.~4. Documented measurable or evaluable ovarian, tubal or primary peritoneal cancer by appropriate radiologic imaging (x-ray, or CT scan). Radiation therapy is allowed as long as not at the site of measurable disease. Recurrent disease based on elevated CA-125 alone is allowed, provided it meets the CA-125 progression definition.~5. Subjects must have adequate hepatic, renal and marrow function (AST/ALT\< 3UNL, creatinine\<2UNL, ANC\>2, HGB\>90)~6. Histologic diagnosis of ovarian, tubal or primary peritoneal cancer.~7. Performance status: ECOG Score greater than or equal to 2.~8. Subjects must have life expectancy of at least 6 months.~9. Women of childbearing potential must have a negative pregnancy test at time of enrollment and must be using an acceptable method of birth- control during the study.~Exclusion Criteria:~1. Female subjects who are pregnant, breast-feeding, or unwilling to use adequate contraception.~2. Any other active primary tumor under treatment, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix;~3. Two or more prior chemotherapy regimens for ovarian cancer~4. Serious infection within one month of commencement of treatment.~5. Patients with known brain metastasis. However baseline CT of the head is not a must.~6. Patients with severe gastro-intestinal symptoms- e.g.- partial obstruction, bleeding or diarrhea.~7. Patients with Grade 2 or higher neuropathy \[NCI Common toxicity criteria\].

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).